U.K. and CA companies to collaborate on breast cancer Dx study

The U.K.'s Abcodia will work with California-based OncoCyte to perfect a blood test for early breast cancer detection. Neither side is disclosing financial terms. The collaboration is expected to focus on OncoCyte's PanC-Dx test, which is also in other clinical studies for bladder, breast and lung cancer. For this new study, OncoCyte will test how well PanC-Dx's cancer markers help detect breast cancer in patient samples supplied from Abcodia's biobank. OncoCyte is a subsidiary of BioTime ($BTX). Release

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.